Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNOTE-146

Affiliations

• ¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
• ² Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, University of Texas, Houston, TX, USA.
• ³ Division of Hematology and Oncology, East Park Medical Group, Houston, TX, USA.
• ⁴ Division of Hematology and Oncology, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, OR, USA.
• ⁵ Medical Oncology/Hematology, Arizona Oncology Associates, Tucson, AZ, USA.
• ⁶ Department of Medicine, Oncology Division, Washington University School of Medicine, St. Louis, MO, USA.
• ⁷ Servicio de Oncología, Hospital Universitario La Paz, Madrid, Spain.
• ⁸ Medical Oncology Service, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
• ⁹ Medical Oncology, US Oncology Research, Rocky Mountain Cancer Center, Denver, CO, USA.
• ¹⁰ Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.
• ¹¹ Medical Oncology, Sorlandet Hospital Kristiansand, Kristiansand, Norway.
• ¹² Sykehuset Østfold, Sarpsborg, Norway.
• ¹³ Department of Oncology, US Oncology Research, Texas Oncology-Tyler, Tyler, TX, USA.
• ¹⁴ Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.
• ¹⁵ Department of Oncology, US Oncology Research, Texas Oncology, Dallas, TX, USA.
• ¹⁶ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
• ¹⁷ Clinical Research, Merck & Co. Inc, Rahway, NJ, USA.
• ¹⁸ Clinical Research, Eisai Inc, Nutley, NJ, USA.
• ¹⁹ Biostatistics, Eisai Inc, Nutley, NJ, USA.
• ²⁰ Clinical Research, Eisai Ltd, Hatfield, UK.
• ²¹ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org.